AEON Biopharma, Inc.

AEON Biopharma, Inc. (Nasdaq: AEON) is a clinical-stage biopharmaceutical company focused on developing proprietary botulinum toxin formulations for therapeutic indications. The company entered public markets through a business combination with Priveterra Acquisition Corp., a healthcare-focused blank-check vehicle that completed its IPO in 2021. An amended quarterly report, Form 10-Q/A under accession number 0001104659-22-029707, was filed with the SEC on March 3, 2022, reflecting updated disclosures following the de-SPAC transaction. Positioned within the healthcare and life sciences sector, AEON's pipeline targets conditions addressable by neuromodulatory compounds. For complete filing history, deal timelines, and sponsor data on AEON and hundreds of other SPACs, sign up for full access at SpacDesk.